Patent ID: 8974812
Filing Date: 2015-03-10
Classification: A61K,A61P

Abstract:
1. A method for treating an ocular condition, the method comprising implanting into an ocular site a drug delivery system, the drug delivery system comprising first, second, and third bioerodible implants suitable for insertion into an ocular region or site, the first bioerodible implant comprising dexamethasone and a poly(D,L-lactide) having an average molecular weight of about 3,500 Daltons; the second bioerodible implant comprising dexamethasone and a poly(D,L-lactide-co-glycolide) having a 75:25 wt %/wt % blend of lactide:glycolide and an average molecular weight of about 40,000 Daltons; and the third bioerodible implant comprising dexamethasone and a poly(D,L-lactide) having an average molecular weight of about 14,000 Daltons, wherein the bioerodible implant can release a therapeutic level of the active agent at a substantially continuous rate upon insertion into an ocular region or site for a period of time between about 30 days and about 1 year.